Antimicrobial Resistance (AMR)

As the leading global provider of generic antibiotics, Sandoz is committed to improving global access to medicine. Our parent company Novartis, one of 130 companies to sign the ‘Davos Declaration’ in January 2016 calling for a collective response to AMR, is also one of 13 companies to sign the subsequent ‘Industry Roadmap’ in September 2016, outlining concrete actions across four areas: access, responsible use, responsible manufacturing and R&D.

We’re equally committed to ensuring the responsible use of medicine. This may mean making some tough business choices as we balance short and long term interests, but we are not alone. Let’s be clear: AMR is a truly global problem, which requires global, multi-stakeholder collaboration.

There are no simple, quick-fix solutions. But with rising political attention and a pledge from industry to play a meaningful role, we have a unique window of opportunity to take concrete steps to combat this growing global threat. Let’s do the right thing, together.

Latest News:

Nov 18, 2021
Joining forces against AMR: A ‘Manhattan Project’ for good
By Global Cause

Thought Leadership:

Nov 18, 2021
Frogs, superbugs and supertankers:
Busting the myths around drug resistance

By Richard Saynor, CEO Sandoz

Oct 11, 2021
Bucking the trend:
Investing in the future of life-saving antibiotics

By Richard Saynor, CEO Sandoz


Sep 21, 2021
Stopping the silent pandemic:
Ramping up action on antimicrobial resistance

By Devex

Source URL:

List of links present in page